Sarepta Plunged After Adverse Event Forces Trial Halt in the UK Post author:Sam Post published:February 11, 2018 Post category:BioPharma But the biotech swiftly indicated that it doesn’t expect the halt to last for long. Source: BioSpace You Might Also Like Boston's InSpire MD Eyes $24.8 Million Series C Round January 25, 2017 Esperion Stock Gains On Strong Phase II Data August 7, 2017 Boston-Based Biotech Inks Immuno-Oncology Pact With Seattle Genetics February 8, 2018
